Reversible retina implants glue impresses

Article

A thermosensitive glue for retinal implants provides an effective in vitro retinal adhesion that is completely reversible by lowering the temperature.

A thermosensitive glue for retinal implants provides an effective in vitro retinal adhesion that is completely reversible by lowering the temperature, according to a report published in the September issue of Retina Journal.

Murat Tunc from Abant Izzet Baysal University, Turkey and colleagues conducted a study to determine the in vitro effects of plasma polymerized N-isopropyl acrylamide (pNIPAM) coating for thermally controllable adhesion to retinal tissue.

Polyimide (50 µm), parylene C (20 µm) and polydimethyl siloxane (PDMS [200 µm]) were coated with pNIPAM and used as implant materials to test retinal adhesion in enucleated pig eyes. Following preparation of the implant materials (n=5) and retina, the researchers held the implants over the retinal tissue at 22°C and gradually increased the temperature of the water bath over a 15-minute period and monitored the adhesion. The adhesive force was measured using a traction test that involved a suture attached to the implant and a strain gauge. The authors also checked the reversibility of the adhesion by lowering the temperature of the water bath.

The results demonstrated that there was no retinal adhesion at room temperature (22°C), however, adhesion developed strongly within 60 seconds of reaching the critical temperature (≥32°C). The adhesion remained when tractional forces of 98 mN and 148 mN were applied between 32 and 38°C. When the temperature was lowered back to 22°C by irrigation with cold BSS, the implants detached from the retinal surface without the use of tractional force.

This study demonstrates that pNIPAM can provide effective retinal adhesion, which is completely reversible by lowering the temperature of the physiologic medium.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.